TOP NEWS

December 11, 2025
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
November 13, 2025
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
November 12, 2025
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
VIEW ALL

WE ARE SOCIAL